The echinocandins, caspofugin, micafungin, and anidulafungin, are lipopeptides that inhibit fungal growth by binding to β -(1.3) d glucan synthase.This enzyme is responsible for the formation of the peptidoglycan cell wall, and it is essential in fungi such as Candida spp, but less important in the case of Aspergillus and Fusarium species.We review the history, pharmacology and clinical trials that have showed clinical effi cacy similar to amphotericin B for the management of fungal infections such as candidemia, invasive candidiasis and aspergillosis, even in cases refractory to initial treatment.These drugs have less toxicity and discontinuation is uncommonly required.Despite similar spectrum and tolerability, there are several pharmacological differences.Only a few clinical trials compare the clinical effi cacy between them and their clinical application cannot be generalized.However, the echinocandins have demonstrated clinical effi cacy in patients with invasive candidiasis and in others forms of systemic mycoses.